NeuroXess
优脑银河
NeuroXess (优脑银河) is a Beijing-based brain science company founded in 2018 by Harvard Medical School professor Hesheng Liu, MIT academicians Robert Desimone and Guoping Feng, and entrepreneur Weike Cheng, who serves as co-founder and CEO . The company develops technology based on functional MRI signals for individualized brain function mapping, positioning itself as an "individual precision brain platform" that helps doctors observe human brain function and connectivity at the neural circuit level . FreeS Fund led its RMB 42 million angel round in 2019 and has continued to back it as part of its brain and neuroscience portfolio, with the company raising over $100 million within two years of that initial round . Its clinical work spans brain tumors, stroke, epilepsy, Alzheimer's, Parkinson's, schizophrenia, and depression, among other conditions .
AI-generated — may contain errors, please verify.
Coverage
Has the Inflection Point for AI for Science Arrived?
Where will the next Nobel Prize emerge?
Congratulations to METiS Pharmaceuticals on its Hong Kong Stock Exchange IPO — FreeS Fund invested in four consecutive early rounds.
From Whiteboard Equations to the "SpaceX" of Pharma
Spend a Summer on a VC Journey of "Seeking Truth" and "Taking Things Seriously" | FreeS Fund's 2024 Internship Program Is Now Open
Welcome aboard — a great workplace is one with a bunch of amazing colleagues.
Every Brain Is a Unique Little Universe | FreeS Fund's World Autism Awareness Day Special
May every life be treated with gentleness.
How to Invest in Biotech in 2023? | FreeS Research
Data-driven, cross-disciplinary, bearing fruit — the most certain direction amid uncertainty
How Can We Further Explore the Human Body's "Smartest" Organ? | FreeS Research Institute
A Few Things About Exploring the Brain
FreeS Fund's Seventh Anniversary: Working Together to Go Further
Welcome to the team.
[Live Tomorrow] In Conversation with Bluepha | Synthetic Biology: From Groping in the Dark to Riding the Wave
Going live tomorrow at 10 a.m. sharp.
What Are the Opportunities for Biotech Over the Next Decade? | A FreeS Fund Conversation
Breaking Through the "Great Stagnation" in Technology: Biotechnology Is a Critical Breakthrough
What Happens When the Hottest Tech Sectors Collide? | FreeS Fund Chip Series
How do cross-disciplinary ventures that push the boundaries of imagination achieve steady, grounded commercialization?
Interdisciplinary Frontier Entrepreneurship: How Chips Are Reshaping Every Industry | May 15 Livestream Registration
See you on May 15!
Farewell to a Year of Inflection Points: Will 2022 Be Better? | Li Feng's New Year Outlook
Where the heart leads, steady steps take you far.
Our Year: Working Together, Staying the Course | FreeS Fund 2021 Year in Review
Walk alongside more outstanding founders.
Going live tonight at 8:30 PM | A conversation on opportunities and trends in the brain science industry
See you at 8:30 tonight.
FreeS Report 24 | Embracing the "Smartest" Opportunity: Investing Boldly in Brain and Neuroscience
If the universe is complex, mysterious, and captivating, so is the brain.
Biotech Firms Raise Nearly 4 Billion Yuan, Consumer Companies Land Over 1.4 Billion | FreeS Family Funding Roundup · August
We've also released three short videos this week — follow us to check them out.
FreeS Fund 2021 Outlook ② | Three Trends in Biomedical Innovation
The Biopharma Industry Enters the "Three Fast" Era
How to Break Through Innovation with the Power of Interdisciplinary Collaboration? | FreeS Fund Biomedical and Pharmaceutical Investment Summit Transcript
What should you do if you discover a mismatch between technology and market?
Blue Ocean Strategy: How Early-Stage Biopharma Startups Can Break Through and Win with Big Pharma | FreeS Fund 2020 Biopharma Summit Session 3 — Registration Open
From "Me Worse" to "First in Class": How Can Biopharma Companies Compete Through Differentiation?
FreeS Fund received eight recognitions from institutions including *Fortune* (Chinese edition), 36Kr, and the Fund of Funds Alliance.
Do what's right, not what's easy.
Our Past 100 Days: Sailing Against the Wind, Growing Toward the Sun
Venture Capital's Pandemic Fight: A Chronicle
Beauty Brands Entering China, Becoming India's Third-Largest E-Commerce Player, and Betting on Biomedical — 22 Developments and 5 Takeaways | FreeS Fund Bulletin · September
Do what's right, not what's easy.
Brain Diseases in Its Crosshairs: NeuroXess Raises $4.2 Million in Angel Round | FreeS Fund Deal News
Brain research remains one of the great unsolved challenges in science.
![[Live Tomorrow] In Conversation with Bluepha | Synthetic Biology: From Groping in the Dark to Riding the Wave](/_next/image?url=https%3A%2F%2Fkkcktdhgzddmdjdjoenc.supabase.co%2Fstorage%2Fv1%2Fobject%2Fpublic%2Fmedia%2Fimages%2F45f83c6a-7c35-4040-ba2d-210c7948ac95%2Fd7061a92cbcc.jpg&w=384&q=75)
